Elutia Inc., was incorporated in Delaware in August 2015. The company develops proprietary drug-eluting biological matrix products for surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. The company's focus is on addressing unmet medical needs and reducing surgery-related complications, including infection, migration, erosion, implant rejection and fibrosis. The company operates across R&D through the commercial distribution of bio-matrix products for plastic and reconstructive surgery.
